<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28373244</article-id><article-id pub-id-type="pmc">5533032</article-id><article-id pub-id-type="doi">10.1161/JAHA.116.005426</article-id><article-id pub-id-type="publisher-id">JAH32155</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Coronary Heart Disease</subject></subj-group></subj-group></article-categories><title-group><article-title>Cardioprotective Effects of Intracoronary Morphine in <styled-content style="fixed-case">ST</styled-content>&#x02010;Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Prospective, Randomized Trial</article-title><alt-title alt-title-type="left-running-head">Gwag et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah32155-cr-0001" contrib-type="author"><name><surname>Gwag</surname><given-names>Hye Bin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32155-aff-0001">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="jah32155-note-1002">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="jah32155-cr-0002" contrib-type="author"><name><surname>Kim</surname><given-names>Eun Kyoung</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32155-aff-0001">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="jah32155-note-1002">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="jah32155-cr-0003" contrib-type="author"><name><surname>Park</surname><given-names>Taek Kyu</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32155-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32155-cr-0004" contrib-type="author"><name><surname>Lee</surname><given-names>Joo Myung</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="jah32155-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32155-cr-0005" contrib-type="author"><name><surname>Yang</surname><given-names>Jeong Hoon</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32155-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32155-cr-0006" contrib-type="author"><name><surname>Song</surname><given-names>Young Bin</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32155-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32155-cr-0007" contrib-type="author"><name><surname>Choi</surname><given-names>Jin&#x02010;Ho</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32155-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32155-cr-0008" contrib-type="author"><name><surname>Choi</surname><given-names>Seung&#x02010;Hyuk</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32155-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32155-cr-0009" contrib-type="author"><name><surname>Lee</surname><given-names>Sang Hoon</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32155-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32155-cr-0010" contrib-type="author"><name><surname>Chang</surname><given-names>Sung&#x02010;A</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32155-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32155-cr-0011" contrib-type="author"><name><surname>Park</surname><given-names>Sung&#x02010;Ji</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32155-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32155-cr-0012" contrib-type="author"><name><surname>Lee</surname><given-names>Sang&#x02010;Chol</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32155-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32155-cr-0013" contrib-type="author"><name><surname>Park</surname><given-names>Seung Woo</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32155-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32155-cr-0014" contrib-type="author"><name><surname>Jang</surname><given-names>Woo Jin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32155-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32155-cr-0015" contrib-type="author"><name><surname>Lee</surname><given-names>Mirae</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32155-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32155-cr-0016" contrib-type="author" corresp="yes"><name><surname>Chun</surname><given-names>Woo Jung</given-names></name><degrees>MD, PhD</degrees><address><email>wj.chun@samsung.com</email></address><xref ref-type="aff" rid="jah32155-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32155-cr-0017" contrib-type="author"><name><surname>Oh</surname><given-names>Ju Hyeon</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32155-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32155-cr-0018" contrib-type="author"><name><surname>Park</surname><given-names>Yong Hwan</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32155-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32155-cr-0019" contrib-type="author"><name><surname>Choe</surname><given-names>Yeon Hyeon</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32155-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah32155-cr-0020" contrib-type="author"><name><surname>Gwon</surname><given-names>Hyeon&#x02010;Cheol</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32155-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32155-cr-0021" contrib-type="author" corresp="yes"><name><surname>Hahn</surname><given-names>Joo&#x02010;Yong</given-names></name><degrees>MD, PhD</degrees><address><email>jyhahn@skku.edu</email></address><xref ref-type="aff" rid="jah32155-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jah32155-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Division of Cardiology</named-content>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<named-content content-type="organisation-division">Samsung Medical Center</named-content>
<institution>Sungkyunkwan University School of Medicine</institution>
<named-content content-type="city">Seoul</named-content>
<country country="KP">Korea</country>
</aff><aff id="jah32155-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Division of Cardiology</named-content>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<named-content content-type="organisation-division">Samsung Changwon Hospital</named-content>
<institution>Sungkyunkwan University School of Medicine</institution>
<named-content content-type="city">Seoul</named-content>
<country country="KP">Korea</country>
</aff><aff id="jah32155-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Division of Radiology</named-content>
<named-content content-type="organisation-division">Samsung Medical Center</named-content>
<institution>Sungkyunkwan University School of Medicine</institution>
<named-content content-type="city">Seoul</named-content>
<country country="KP">Korea</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Joo&#x02010;Yong Hahn, MD, PhD, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, #81 Irwon&#x02010;ro, Gangnam&#x02010;gu, Seoul 06351, Korea. E&#x02010;mail: <email>jyhahn@skku.edu</email> or<break/>
Woo Jung Chun, MD, PhD, Cardiac and Vascular Center, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, #50 Hapsung&#x02010;Dong, Masan Hoewon&#x02010;Gu, Changwon&#x02010;Si, Gyeongsangnam&#x02010;Do 135&#x02010;710, Korea. E&#x02010;mail: <email>wj.chun@samsung.com</email><break/></corresp><fn fn-type="equal" id="jah32155-note-1002"><label>&#x02020;</label><p>Dr Gwag and Dr Kim contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>03</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2017</year></pub-date><volume>6</volume><issue>4</issue><issue-id pub-id-type="doi">10.1002/jah3.2017.6.issue-4</issue-id><elocation-id>e005426</elocation-id><history><date date-type="received"><day>28</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>02</day><month>3</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-6-e005426.pdf"/><abstract id="jah32155-abs-0001"><sec id="jah32155-sec-0001"><title>Background</title><p>A cardioprotective role of morphine acting via opioid receptors has been demonstrated, and previous preclinical studies have reported that morphine could reduce reperfusion injury and myocardial infarct size in a way similar to that of ischemic periconditioning. This study aimed to evaluate the effect of intracoronary morphine on myocardial infarct size in patients with <styled-content style="fixed-case">ST</styled-content>&#x02010;elevation myocardial infarction undergoing primary percutaneous coronary intervention.</p></sec><sec id="jah32155-sec-0002"><title>Methods and Results</title><p>This study was designed as a 2&#x02010;center, prospective, randomized, open&#x02010;label, blinded end point trial. A total of 91 <styled-content style="fixed-case">ST</styled-content>&#x02010;elevation myocardial infarction patients with thrombolysis in myocardial infarction flow grade of 0 to 1 undergoing primary percutaneous coronary intervention were randomly assigned to a morphine or control group at a 1:1 ratio. The morphine group received 3&#x000a0;mg of morphine sulfate diluted with 3&#x000a0;mL of normal saline, and the control group received 3&#x000a0;mL of normal saline into a coronary artery immediately after restoration of coronary flow. The primary end point was myocardial infarct size assessed by cardiac magnetic resonance imaging The cardiac magnetic resonance images were evaluated for 42 and 38 patients in the morphine and control groups, respectively. Myocardial infarct size was not different between the 2 groups (25.6&#x000b1;11.2% versus 24.6&#x000b1;10.5%, <italic>P</italic>=0.77), nor was the extent of microvascular obstruction or myocardial salvage index (6.0&#x000b1;6.3% versus 5.1&#x000b1;4.6%, <italic>P</italic>=0.91; 31.1&#x000b1;15.2% versus 30.3&#x000b1;10.9%, <italic>P</italic>=0.75, respectively). There was no difference in peak creatine kinase&#x02010;<styled-content style="fixed-case">MB</styled-content> level, final thrombolysis in myocardial infarction flow, myocardial brush grade, or complete resolution of <styled-content style="fixed-case">ST</styled-content>&#x02010;segment.</p></sec><sec id="jah32155-sec-0003"><title>Conclusions</title><p>Intracoronary morphine administration could not reduce myocardial infarct size in <styled-content style="fixed-case">ST</styled-content>&#x02010;elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.</p></sec><sec id="jah32155-sec-0004"><title>Clinical Trial Registration</title><p>
<styled-content style="fixed-case">URL</styled-content>: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>. Unique identifier: <styled-content style="fixed-case">NCT</styled-content>01738100.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah32155-kwd-0001">cardiac magnetic resonance imaging</kwd><kwd id="jah32155-kwd-0002">intracoronary morphine</kwd><kwd id="jah32155-kwd-0003">percutaneous coronary intervention</kwd><kwd id="jah32155-kwd-0004">reperfusion injury</kwd><kwd id="jah32155-kwd-0005"><styled-content style="fixed-case">ST</styled-content>&#x02010;segment elevation myocardial infarction</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Acute Coronary Syndromes</kwd><kwd>Magnetic Resonance Imaging (MRI)</kwd><kwd>Pharmacology</kwd></kwd-group><funding-group><award-group><funding-source>Sungkyunkwan University Foundation for Corporate Collaboration</funding-source><award-id>CB28051</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="12"/><word-count count="6015"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jah32155</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.3 mode:remove_FC converted:11.07.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jah32155-cit-1001">(<source>J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e005426</elocation-id> DOI: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.116.005426">10.1161/JAHA.116.005426</ext-link>.)<pub-id pub-id-type="pmid">28373244</pub-id></mixed-citation>
</p></notes></front><body><sec id="jah32155-sec-0005"><title>Introduction</title><p>Since the introduction of primary percutaneous coronary intervention (PCI), the mortality of ST&#x02010;segment elevation acute myocardial infarction (STEMI) has been dramatically reduced to below 10%.<xref rid="jah32155-bib-0001" ref-type="ref">1</xref> However, a significant number of patients are still at risk for cardiac death or heart failure due to left ventricular systolic dysfunction.<xref rid="jah32155-bib-0002" ref-type="ref">2</xref> This is because blood flow restoration in the epicardial coronary artery is not identical to myocardial perfusion, and myocardial perfusion may be more important.<xref rid="jah32155-bib-0003" ref-type="ref">3</xref>, <xref rid="jah32155-bib-0004" ref-type="ref">4</xref> Myocardial damage occurs not only during the ischemic period but also during reperfusion; this is called reperfusion injury. The benefit of reperfusion is limited by this phenomenon during the first few minutes after restoration of blood flow.<xref rid="jah32155-bib-0005" ref-type="ref">5</xref>, <xref rid="jah32155-bib-0006" ref-type="ref">6</xref> Recently, several strategies have been attempted to reduce reperfusion injury and myocardial infarct size.<xref rid="jah32155-bib-0007" ref-type="ref">7</xref> Among several pharmacological agents, morphine has demonstrated a cardioprotective effect via opioid receptors, and previous laboratory and animal studies have reported that morphine could reduce reperfusion injury and myocardial infarct size in a way similar to that of ischemic periconditioning.<xref rid="jah32155-bib-0008" ref-type="ref">8</xref>, <xref rid="jah32155-bib-0009" ref-type="ref">9</xref>, <xref rid="jah32155-bib-0010" ref-type="ref">10</xref> However, to date, limited data are available on the cardioprotective effects of morphine in STEMI.</p><p>Regarding route of administration, several studies have suggested that intracoronary injection of cardioactive drugs showed superior efficacy compared with intravenous application.<xref rid="jah32155-bib-0011" ref-type="ref">11</xref>, <xref rid="jah32155-bib-0012" ref-type="ref">12</xref>, <xref rid="jah32155-bib-0013" ref-type="ref">13</xref> Morphine may be more protective against reperfusion injury by intracoronary injection compared with intravenous injection. Therefore, we conducted a randomized trial to compare the effects of intracoronary morphine administration on myocardial infarct size in STEMI patients undergoing primary PCI using cardiac magnetic resonance imaging (CMR).</p></sec><sec id="jah32155-sec-0006"><title>Methods</title><sec id="jah32155-sec-0007"><title>Study Design and Patients</title><p>This study was designed as a 2&#x02010;center, prospective, randomized open&#x02010;label, blinded end point study. The study incorporated 2 sequential randomized phases to allow a comparison of ticagrelor with clopidogrel and a comparison of intracoronary morphine with intracoronary saline with regard to myocardial infarct size. Eligible patients were those who had STEMI and planned primary PCI. Inclusion criteria were the presence of chest pain for less than 12&#x000a0;hours after symptom onset and ST&#x02010;segment elevation of more than 1&#x000a0;mm in more than 2 contiguous leads. We excluded patients with the following features: (1) hemodynamic instability; (2) rescue PCI after thrombolysis or facilitated PCI; (3) noncardiac comorbidities with life expectancy of &#x0003c;1&#x000a0;year or that might result in protocol noncompliance according to the investigator's medical judgment; (4) female of childbearing potential, unless a recent pregnancy test was negative, or planning to become pregnant any time after enrollment; (5) contraindications to study medications or contrast agent; (6) receiving clopidogrel 300&#x000a0;mg or more before the first randomization; (7) a history of previous myocardial infarction; or (8) contraindications to CMR. Hemodynamic instability was defined as cardiogenic shock, respiratory failure, ventricular tachyarrhythmias requiring electrical cardioversion or defibrillation, or any situation in need of cardiopulmonary resuscitation or percutaneous cardiopulmonary support. The protocol was approved by the local institutional review board, and written informed consent was obtained from all participants. The study protocol was registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> (NCT01738100).</p></sec><sec id="jah32155-sec-0008"><title>Randomization and Study Procedures</title><p>The first randomization assigned patients to the ticagrelor group or the clopidogrel group in a 1:1 ratio. In the ticagrelor group patients received a 180&#x02010;mg loading dose followed by a maintenance dose of 90&#x000a0;mg twice daily. In the clopidogrel group, patients received a 600&#x02010;mg loading dose followed by a daily maintenance dose of 75&#x000a0;mg. The results of the comparison between P2Y<sub>12</sub> inhibitors will be reported elsewhere. The second randomization was performed after diagnostic angiography. Patients with a thrombolysis in myocardial infarction (TIMI) flow grade of 0 or 1 in the culprit vessel were randomly assigned to receive a bolus intracoronary (IC) injection of either morphine sulfate or saline at a 1:1 ratio. Randomization was performed with a web&#x02010;based response system (<ext-link ext-link-type="uri" xlink:href="http://www.ecrf.kr/tica">www.ecrf.kr/tica</ext-link>) and stratified by the enrollment site and infarct location (anterior or nonanterior).</p><p>All patients received 300&#x000a0;mg of aspirin unless they had previously taken this medication. Intravenous heparin was administered to maintain an activated clotting time of &#x0003e;250&#x000a0;seconds. Coronary angiography and stent implantation were performed using standard interventional techniques. Thrombus aspiration, balloon predilation and postdilation, type of stents, use of glycoprotein IIb/IIIa inhibitors, and intravascular imaging were left to the operators' discretion. In the IC morphine group, 3&#x000a0;mg of morphine sulfate diluted with 3&#x000a0;mL of normal saline was injected into a coronary artery immediately after restoration (TIMI grade &#x02265;2) of coronary flow regardless of the method of restoration. In the control group, patients received an IC injection of 3&#x000a0;mL normal saline instead.</p><p>The myocardial band fraction of creatine kinase (CK&#x02010;MB) was measured before PCI and every 8&#x000a0;hours for 2&#x000a0;days after the index procedure. Then CK&#x02010;MB was measured once daily until the level was normalized. Twelve&#x02010;lead ECGs were obtained before and 30&#x000a0;minutes after the procedure. The definition of complete ST&#x02010;segment resolution was a decrement in the sum of ST&#x02010;segment elevation of 70% or more.<xref rid="jah32155-bib-0014" ref-type="ref">14</xref> TIMI flow and myocardial blush grades were evaluated by standard methods.<xref rid="jah32155-bib-0015" ref-type="ref">15</xref> ECG and angiographic analyses, which included postprocedural TIMI flow grade, myocardial blush grade, and complete ST&#x02010;segment resolution at 30 and 60&#x000a0;minutes after the procedure, were performed by&#x000a0;2 independent observers blinded to the study group assignment.</p><p>Both groups received 100&#x000a0;mg of aspirin daily. We recommended optimal pharmacological therapy in all patients, which included statins, &#x003b2;&#x02010;blockers, or renin&#x02010;angiotensin system blockers according to current guidelines.<xref rid="jah32155-bib-0016" ref-type="ref">16</xref>
</p></sec><sec id="jah32155-sec-0009"><title>Cardiac Magnetic Resonance Imaging and Analysis</title><p>CMR was performed within 5&#x000a0;days after the index event, and CMR images were acquired on a 1.5&#x02010;T scanner (Magnetom Avanto, Syngo MR B15 version; Siemens Medical Solutions, Erlangen, Germany) with a 32&#x02010;channel phased&#x02010;array receiver coil. Cine images were acquired using a steady&#x02010;state free&#x02010;precession sequence with 8 to 10 contiguous short&#x02010;axis slices to cover the entire left ventricle (LV) with a slice thickness of 6&#x000a0;mm and a 4&#x02010;mm gap. T2&#x02010;weighted imaging was performed in the continuous short&#x02010;axis direction using a dark&#x02010;blood inversion recovery fast&#x02010;spin echo sequence before contrast was administered. A phase&#x02010;sensitive inversion recovery technique was used for standard delayed gadolinium&#x02010;enhanced imaging. The field of view and image matrix were 35&#x000d7;35 and 256&#x000d7;256&#x000a0;cm, respectively.</p><p>All measurements were performed at our CMR core laboratory by an experienced observer blinded to patient data using commercialized software (CAAS MRV version 1.0, Pie Medical Imaging BV, Maastricht, The Netherlands). Infarct size was defined as the proportion of delayed hyperenhancement to LV myocardial volume, and hypoenhanced region surrounded by a hyperenhanced area was considered a sign of microvascular obstruction (MVO).<xref rid="jah32155-bib-0017" ref-type="ref">17</xref> The myocardial salvage index was calculated as (area&#x02010;at risk&#x02212;infarct size)&#x000d7;100/area&#x02010;at risk. Transmural infarct extent was expressed as a percentage of infarct thickness and categorized into 5 transmural scores. Infarct thickness was defined as the enhanced wall thickness/total wall thickness of the infarct LV segment. A transmural score was categorized according to infarct thickness: 0, no infarction; 1, 1% to 25%; 2, 26% to 50%; 3, 51% to 75%; and 4, 76% to 100% of wall thickness. The mean infarct transmurality score was calculated by dividing the sum of hyperenhancement segmental scores by the number of segments with any delayed hyperenhancement.<xref rid="jah32155-bib-0018" ref-type="ref">18</xref>
</p></sec><sec id="jah32155-sec-0010"><title>Study End points</title><p>The primary end point was myocardial infarct size (percentage LV volume) assessed by CMR. Secondary end points included the extent of MVO and myocardial salvage index, postprocedural TIMI flow grade, myocardial blush grade, complete ST&#x02010;segment resolution at 30&#x000a0;minutes after the procedure, and peak CK&#x02010;MB level. The definition of complete ST&#x02010;segment resolution was a decrement in the sum of ST&#x02010;segment elevation of 70% or more.<xref rid="jah32155-bib-0014" ref-type="ref">14</xref> TIMI flow and myocardial blush grades were evaluated by standard methods.<xref rid="jah32155-bib-0015" ref-type="ref">15</xref> ECG and angiographic analyses, which included postprocedural TIMI flow grade, myocardial blush grade, and complete ST&#x02010;segment resolution at 30 and 60&#x000a0;minutes after the procedure, were performed by 2 independent observers blinded to study group assignment. In&#x02010;hospital complications after primary PCI included death, intra&#x02010;aortic balloon pump use, acute pulmonary edema, bleeding, recurrent ischemia, stent thrombosis, arrhythmias, stroke, or infection. Major adverse cardiac events included death, MI, and hospital readmission for heart failure at 6&#x000a0;months based on the definition used in our previous study.<xref rid="jah32155-bib-0014" ref-type="ref">14</xref>
</p></sec><sec id="jah32155-sec-0011"><title>Statistical Analysis</title><p>The expected SD for myocardial infarct size was estimated to be 10% based on the previous study, and a relative reduction of 30% in infarct size from 25% to 17.5% was considered significant.<xref rid="jah32155-bib-0013" ref-type="ref">13</xref>, <xref rid="jah32155-bib-0015" ref-type="ref">15</xref> For a power of 0.90 and an &#x003b1; error of 0.05, the estimated sample size needed to be 38 patients in each group. The final sample size of 45 was chosen to account for up to 15% unavailable CMR studies in each group. The Statistical Analysis Software package (SPSS Inc, Chicago, IL) was used for all analyses. Continuous variables were expressed as the median and interquartile range or the mean&#x000b1;SD and compared using t test or Mann&#x02010;Whitney U nonparametric test as appropriate. Categorical variables were expressed as counts or percentages and analyzed using Pearson chi&#x02010;squared or Fisher exact tests. We also performed subgroup analyses to evaluate the consistency of treatment effects of morphine using generalized linear models. All tests were 2 sided, and <italic>P</italic> values less than 0.05 were considered statistically significant.</p></sec></sec><sec id="jah32155-sec-0012"><title>Results</title><sec id="jah32155-sec-0013"><title>Baseline Characteristics</title><p>During the study period, a total of 110 patients undergoing primary PCI were randomly assigned to the ticagrelor group or the clopidogrel group. Of these, 91 patients with TIMI flow grade of 0 to 1 were randomly assigned to the IC morphine group (n=45) or the control group (n=46). We excluded patients with symptom&#x02010;to&#x02010;balloon time more than 12&#x000a0;hours (n=1), previous history of myocardial infarction (n=1), hemodynamic instability (n=1), concurrent brain tumor (n=1), withdrawal from the trial (n=3), or refusal to CMR (n=4). Finally, CMR could be evaluated in 42 patients in the IC morphine group and 38 patients in the control group (Figure&#x000a0;<xref rid="jah32155-fig-0001" ref-type="fig">1</xref>). Baseline characteristics are shown in Table&#x000a0;<xref rid="jah32155-tbl-0001" ref-type="table-wrap">1</xref>. There were no significant differences in baseline demographic and laboratory findings between the IC morphine and control groups. The median age of the total patients was 60&#x000a0;years (49.5&#x02010;66.5&#x000a0;years). More than 80% of patients were male in both groups. There was no significant difference in use of P2Y<sub>12</sub> receptor inhibitor (ticagrelor or clopidogrel). Angiographic and procedural findings were well balanced between the groups as well. Forty&#x02010;two patients (52.5%) had 1&#x02010;vessel disease, and the left anterior descending artery was the most commonly involved coronary artery. Most patients underwent stent implantation in the culprit coronary artery.</p><fig fig-type="Figure" xml:lang="en" id="jah32155-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Study flow. <styled-content style="fixed-case">CMR</styled-content> indicates cardiac magnetic resonance; <styled-content style="fixed-case">IC</styled-content>, intracoronary; <styled-content style="fixed-case">MI</styled-content>, myocardial infarction; <styled-content style="fixed-case">PCI</styled-content>, percutaneous coronary intervention; <styled-content style="fixed-case">TIMI</styled-content>, thrombolysis in myocardial infarction.</p></caption><graphic id="nlm-graphic-1" xlink:href="JAH3-6-e005426-g001"/></fig><table-wrap id="jah32155-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline Characteristics</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">IC Morphine (n=42)</th><th align="left" valign="top" rowspan="1" colspan="1">Control (n=38)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, y</td><td align="left" rowspan="1" colspan="1">57.5 (49.0&#x02010;66.0)</td><td align="left" rowspan="1" colspan="1">62.0 (50.0&#x02010;67.0)</td><td align="left" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">37 (88.1)</td><td align="left" rowspan="1" colspan="1">31 (81.6)</td><td align="left" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1">Height, cm</td><td align="left" rowspan="1" colspan="1">168.0 (162.0&#x02010;173.0)</td><td align="left" rowspan="1" colspan="1">167.5 (164.0&#x02010;171.0)</td><td align="left" rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight, kg</td><td align="left" rowspan="1" colspan="1">69.2 (63.9&#x02010;76.2)</td><td align="left" rowspan="1" colspan="1">67.4 (59.3&#x02010;72.3)</td><td align="left" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">17 (40.5)</td><td align="left" rowspan="1" colspan="1">14 (36.8)</td><td align="left" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="left" rowspan="1" colspan="1">10 (23.8)</td><td align="left" rowspan="1" colspan="1">9 (23.7)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidemia</td><td align="left" rowspan="1" colspan="1">11 (26.2)</td><td align="left" rowspan="1" colspan="1">10 (26.3)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="left" rowspan="1" colspan="1">33 (78.6)</td><td align="left" rowspan="1" colspan="1">28 (73.7)</td><td align="left" rowspan="1" colspan="1">0.79</td></tr><tr><td align="left" rowspan="1" colspan="1">History of CVA</td><td align="left" rowspan="1" colspan="1">4 (9.5)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelet count, &#x000d7;10<sup>6</sup>
</td><td align="left" rowspan="1" colspan="1">233 (205&#x02010;270)</td><td align="left" rowspan="1" colspan="1">221 (191&#x02010;249)</td><td align="left" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol, mg/dL</td><td align="left" rowspan="1" colspan="1">201 (183&#x02010;230)</td><td align="left" rowspan="1" colspan="1">193 (169&#x02010;216)</td><td align="left" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL, mg/dL</td><td align="left" rowspan="1" colspan="1">137.5 (117.0&#x02010;161.0)</td><td align="left" rowspan="1" colspan="1">117.0 (104.5&#x02010;142.5)</td><td align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum creatinine, mg/dL</td><td align="left" rowspan="1" colspan="1">0.98 (0.83&#x02010;1.07)</td><td align="left" rowspan="1" colspan="1">0.90 (0.79&#x02010;1.05)</td><td align="left" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial glucose, mg/dL</td><td align="left" rowspan="1" colspan="1">157 (137&#x02010;179)</td><td align="left" rowspan="1" colspan="1">141 (123&#x02010;173)</td><td align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">Hs&#x02010;CRP, mg/dL</td><td align="left" rowspan="1" colspan="1">0.11 (0.04&#x02010;0.29)</td><td align="left" rowspan="1" colspan="1">0.08 (0.05&#x02010;0.18)</td><td align="left" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1">Symptom to balloon time, minutes</td><td align="left" rowspan="1" colspan="1">167 (112&#x02010;283)</td><td align="left" rowspan="1" colspan="1">158 (108&#x02010;243)</td><td align="left" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">Door to balloon time, minutes</td><td align="left" rowspan="1" colspan="1">67 (53&#x02010;76)</td><td align="left" rowspan="1" colspan="1">69 (51&#x02010;78)</td><td align="left" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" colspan="4" rowspan="1">Culprit vessel</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">LAD</td><td align="left" rowspan="1" colspan="1">23 (54.8)</td><td align="left" rowspan="1" colspan="1">21 (55.3)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">LCX</td><td align="left" rowspan="1" colspan="1">3 (7.1)</td><td align="left" rowspan="1" colspan="1">3 (7.9)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">RCA</td><td align="left" rowspan="1" colspan="1">16 (38.1)</td><td align="left" rowspan="1" colspan="1">14 (36.8)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td align="left" colspan="4" rowspan="1">Number of diseased vessels</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">22 (52.4)</td><td align="left" rowspan="1" colspan="1">20 (52.6)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">14 (33.3)</td><td align="left" rowspan="1" colspan="1">15 (39.5)</td><td align="left" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">6 (14.3)</td><td align="left" rowspan="1" colspan="1">3 (7.9)</td><td align="left" rowspan="1" colspan="1">0.49</td></tr><tr><td align="left" rowspan="1" colspan="1">Lesion type B2/C</td><td align="left" rowspan="1" colspan="1">38 (90.5)</td><td align="left" rowspan="1" colspan="1">36 (94.7)</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" colspan="4" rowspan="1">Initial TIMI flow grade</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">38 (90.5)</td><td align="left" rowspan="1" colspan="1">37 (97.4)</td><td align="left" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">4 (9.5)</td><td align="left" rowspan="1" colspan="1">1 (2.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Thrombus aspiration</td><td align="left" rowspan="1" colspan="1">27 (64.3)</td><td align="left" rowspan="1" colspan="1">25 (65.8)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td align="left" rowspan="1" colspan="1">Stent insertion</td><td align="left" rowspan="1" colspan="1">42 (100)</td><td align="left" rowspan="1" colspan="1">36 (94.7)</td><td align="left" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stent diameter, mm</td><td align="left" rowspan="1" colspan="1">3.0 (2.75&#x02010;3.5)</td><td align="left" rowspan="1" colspan="1">3.0 (2.75&#x02010;3.5)</td><td align="left" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stent length, mm</td><td align="left" rowspan="1" colspan="1">28 (23&#x02010;30)</td><td align="left" rowspan="1" colspan="1">27 (19&#x02010;33)</td><td align="left" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" colspan="4" rowspan="1">P2Y<sub>12</sub> receptor inhibitor</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Clopidogrel</td><td align="left" rowspan="1" colspan="1">25 (59.5)</td><td align="left" rowspan="1" colspan="1">20 (52.6)</td><td align="left" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ticagrelor</td><td align="left" rowspan="1" colspan="1">17 (40.5)</td><td align="left" rowspan="1" colspan="1">18 (47.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Glycoprotein IIb/IIIa inhibitors</td><td align="left" rowspan="1" colspan="1">4 (9.5)</td><td align="left" rowspan="1" colspan="1">3 (7.9)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.999</td></tr></tbody></table><table-wrap-foot><fn id="jah32155-note-0003"><p>Values are reported as median (25<sup>th</sup>&#x02010;75th percentiles) or n (%). CVA indicates cerebrovascular accident; Hs&#x02010;CRP, high&#x02010;sensitivity C&#x02010;reactive protein; IC, intracoronary; LAD, left anterior descending; LCX, left circumflex; LDL, low&#x02010;density lipoprotein; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="jah32155-sec-0014"><title>Cardiac Magnetic Resonance Results</title><p>There was no significant difference in the intervals from PCI to CMR between the 2 groups (3 [3&#x02010;4] days for both groups, <italic>P</italic>=0.88). CMR data are shown in Table&#x000a0;<xref rid="jah32155-tbl-0002" ref-type="table-wrap">2</xref>. LV mass was significantly smaller in the control group, but both primary and secondary outcomes did not show any differences between the groups. The primary outcome, myocardial infarct size, was similar (25.6&#x000b1;11.2% vs 24.6&#x000b1;10.5%, <italic>P</italic>=0.77) between the 2 groups, as were other CMR parameters including MVO extent and myocardial salvage index (Figure&#x000a0;<xref rid="jah32155-fig-0002" ref-type="fig">2</xref>). In subgroup analysis the neutral effect of IC morphine was consistent among the various subgroups, but there was significant interaction between the treatment effect of IC morphine during primary PCI and prior use of morphine. IC morphine tended to decrease infarct size in patients receiving morphine before randomization (Figure&#x000a0;<xref rid="jah32155-fig-0003" ref-type="fig">3</xref>).</p><table-wrap id="jah32155-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>CMR Findings</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">IC Morphine (n=42)</th><th align="left" valign="top" rowspan="1" colspan="1">Control (n=38)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">LV end&#x02010;diastolic volume, mL</td><td align="left" rowspan="1" colspan="1">143.7&#x000b1;31.0</td><td align="left" rowspan="1" colspan="1">139.9&#x000b1;28.7</td><td align="left" rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" rowspan="1" colspan="1">LV end&#x02010;systolic volume, mL</td><td align="left" rowspan="1" colspan="1">67.6&#x000b1;25.6</td><td align="left" rowspan="1" colspan="1">67.2&#x000b1;20.9</td><td align="left" rowspan="1" colspan="1">0.90</td></tr><tr><td align="left" rowspan="1" colspan="1">LV ejection fraction, %</td><td align="left" rowspan="1" colspan="1">53.9&#x000b1;10.0</td><td align="left" rowspan="1" colspan="1">52.4&#x000b1;7.8</td><td align="left" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" rowspan="1" colspan="1">LV mass, mL</td><td align="left" rowspan="1" colspan="1">116.2&#x000b1;27.7</td><td align="left" rowspan="1" colspan="1">104.7&#x000b1;23.5</td><td align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Infarct size (%LV)</td><td align="left" rowspan="1" colspan="1">25.6&#x000b1;11.2</td><td align="left" rowspan="1" colspan="1">24.6&#x000b1;10.5</td><td align="left" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" rowspan="1" colspan="1">Area at risk (%LV)</td><td align="left" rowspan="1" colspan="1">35.7&#x000b1;11.9</td><td align="left" rowspan="1" colspan="1">34.4&#x000b1;13.2</td><td align="left" rowspan="1" colspan="1">0.59</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial salvage index, %</td><td align="left" rowspan="1" colspan="1">31.1&#x000b1;15.2</td><td align="left" rowspan="1" colspan="1">30.3&#x000b1;10.9</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Extent of MVO (%LV)</td><td align="left" rowspan="1" colspan="1">6.0&#x000b1;6.3</td><td align="left" rowspan="1" colspan="1">5.1&#x000b1;4.6</td><td align="left" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean transmurality score</td><td align="left" rowspan="1" colspan="1">2.1&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">2.0&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of segments with transmural infarction &#x02265;75%</td><td align="left" rowspan="1" colspan="1">3 (2&#x02010;6)</td><td align="left" rowspan="1" colspan="1">4 (2&#x02010;6)</td><td align="left" rowspan="1" colspan="1">0.86</td></tr></tbody></table><table-wrap-foot><fn id="jah32155-note-0004"><p>Values are reported as mean&#x000b1;SD or median (25th&#x02010;75th percentiles). CMR indicates cardiac magnetic resonance; intracoronary; LV, left ventricle; MVO, microvascular obstruction.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="jah32155-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Myocardial infarct size in the intracoronary morphine and saline group. <styled-content style="fixed-case">IC</styled-content> indicates intracoronary; LV, left ventricle.</p></caption><graphic id="nlm-graphic-3" xlink:href="JAH3-6-e005426-g002"/></fig><fig fig-type="Figure" xml:lang="en" id="jah32155-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Forest plot subgroup analyses for myocardial infarct size. <styled-content style="fixed-case">CI</styled-content> indicates confidence interval; <styled-content style="fixed-case">IC</styled-content>, intracoronary; IV, intravenous; LV, left ventricle; <styled-content style="fixed-case">MI</styled-content>, myocardial infarction.</p></caption><graphic id="nlm-graphic-5" xlink:href="JAH3-6-e005426-g003"/></fig></sec><sec id="jah32155-sec-0015"><title>Angiographic, ECG, Biochemical, and Clinical Outcomes</title><p>Angiographic, ECG, and biochemical outcomes are displayed in Table&#x000a0;<xref rid="jah32155-tbl-0003" ref-type="table-wrap">3</xref>. All but 1 patient achieved final TIMI flow grade of 3, and the prevalence of postprocedural myocardial blush grade 2 to 3 was similar in both groups. The frequency of complete ST&#x02010;segment resolution 30&#x000a0;minutes after PCI and peak CK&#x02010;MB levels were not different between the 2 groups. In&#x02010;hospital complications and pharmacologic therapy did not show differences between the IC morphine and the control group (Tables <xref rid="jah32155-sup-0001" ref-type="supplementary-material">S1</xref> and <xref rid="jah32155-sup-0001" ref-type="supplementary-material">S2</xref>). During the 6&#x02010;month follow&#x02010;up, only 1 patient in the IC morphine group was admitted for heart failure management.</p><table-wrap id="jah32155-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Angiographic, ECG, and Biochemical Outcomes</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">IC Morphine (n=42)</th><th align="left" valign="top" rowspan="1" colspan="1">Control (n=38)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Final TIMI flow grade</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1 (2.4)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">41 (97.6)</td><td align="left" rowspan="1" colspan="1">38 (100)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial blush grade</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">0/1</td><td align="left" rowspan="1" colspan="1">9 (21.4)</td><td align="left" rowspan="1" colspan="1">9 (23.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">13 (31.0)</td><td align="left" rowspan="1" colspan="1">12 (31.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">20 (47.6)</td><td align="left" rowspan="1" colspan="1">17 (44.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Complete ST resolution at 30&#x000a0;minutes</td><td align="left" rowspan="1" colspan="1">16 (38.1)</td><td align="left" rowspan="1" colspan="1">14 (36.8)</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td align="left" rowspan="1" colspan="1">Complete ST resolution at 60&#x000a0;minutes</td><td align="left" rowspan="1" colspan="1">18 (42.9)</td><td align="left" rowspan="1" colspan="1">21 (55.3)</td><td align="left" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">Peak CK&#x02010;MB, ng/mL</td><td align="left" rowspan="1" colspan="1">231 (133.6&#x02010;307.0)</td><td align="left" rowspan="1" colspan="1">234.9 (110.1&#x02010;288.7)</td><td align="left" rowspan="1" colspan="1">0.54</td></tr></tbody></table><table-wrap-foot><fn id="jah32155-note-0005"><p>Values are reported as median (25th&#x02010;75th percentiles) or n (%). CK&#x02010;MB indicates creatine kinase&#x02010;myocardial band fraction; ECG, electrocardiogram; IC, intracoronary; TIMI, thrombolysis in myocardial infarction.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec></sec><sec id="jah32155-sec-0016"><title>Discussion</title><p>In this prospective randomized study we investigated whether IC morphine administration could reduce the size of myocardial infarction in STEMI patients undergoing primary PCI. The major finding of this study was that IC morphine administration could not reduce myocardial infarct size evaluated by CMR compared with the control group. There were no differences in myocardial salvage index or the extent of MVO between the 2 groups either. Other estimates of myocardial injury including ST&#x02010;segment resolution and a peak CK&#x02010;MB level showed no difference between groups. Exploratory subgroup analyses showed consistent neutral effects of morphine in various subgroups. To our knowledge, this is the first prospective randomized study to evaluate the cardioprotective effect of IC morphine in STEMI patients undergoing primary PCI using CMR.</p><p>Primary PCI has been shown to be an effective reperfusion therapy for STEMI to restore coronary artery blood flow and has contributed to reducing mortality of STEMI.<xref rid="jah32155-bib-0001" ref-type="ref">1</xref> However, abrupt reperfusion after prolonged coronary occlusion can induce myocardial and vascular injury. The beneficial effects of primary PCI are limited by reperfusion injury, and lethal reperfusion injury is reported to account for up to 50% of the final size of a myocardial infarct.<xref rid="jah32155-bib-0019" ref-type="ref">19</xref> Although several cardioprotective strategies have been attempted to prevent reperfusion injury and to reduce myocardial infarct size, none of them has been definitively proven to be effective.<xref rid="jah32155-bib-0010" ref-type="ref">10</xref>, <xref rid="jah32155-bib-0020" ref-type="ref">20</xref>, <xref rid="jah32155-bib-0021" ref-type="ref">21</xref>, <xref rid="jah32155-bib-0022" ref-type="ref">22</xref> Considering the high mortality and substantial rate of patients with LV dysfunction after STEMI, identifying an effective therapy for preventing lethal reperfusion injury is highly demanding. Therefore, we conducted the present trial to investigate the beneficial effects of IC morphine on myocardial infarct size in patients undergoing primary PCI.</p><p>Morphine has been used to control nitrate&#x02010;unresponsive chest pain in acute myocardial infarction.<xref rid="jah32155-bib-0016" ref-type="ref">16</xref>, <xref rid="jah32155-bib-0023" ref-type="ref">23</xref> Apart from its analgesic effects, morphine can also lower myocardial oxygen demand by reducing sympathetic activation and dilating peripheral vessels.<xref rid="jah32155-bib-0024" ref-type="ref">24</xref> Moreover, previous laboratory and animal data reported a protective effect of morphine and its derivatives for prevention of reperfusion injury. Additionally, a cardioprotective role of morphine via opioid receptors has been demonstrated, and previous studies have reported that morphine can reduce reperfusion injury and infarct size of the myocardium in a way similar to that of ischemic periconditioning.<xref rid="jah32155-bib-0010" ref-type="ref">10</xref>, <xref rid="jah32155-bib-0025" ref-type="ref">25</xref> One previous clinical trial showed that remote ischemic periconditioning and morphine infusion played a preventive role in reperfusion injury of STEMI patients.<xref rid="jah32155-bib-0025" ref-type="ref">25</xref> It compared the efficacy of 3 treatment groups: control, remote ischemic periconditioning alone, or remote ischemic periconditioning plus morphine infusion. The last group showed the best efficacy, and the authors suggested a potential role of opioid action in ischemic postconditioning. Thus, we conducted a prospective, randomized trial on STEMI patients and analyzed myocardial infarct size using CMR images to investigate the cardioprotective role of morphine more accurately and directly. We administered morphine into the coronary artery expecting superior efficacy based on recent studies implying improved results with intracoronary injection of cardioactive drugs compared with intravenous application.<xref rid="jah32155-bib-0011" ref-type="ref">11</xref>, <xref rid="jah32155-bib-0012" ref-type="ref">12</xref>, <xref rid="jah32155-bib-0013" ref-type="ref">13</xref>
</p><p>In our present study we demonstrated that IC morphine during primary PCI did not reduce myocardial infarct size, but there is a possibility that our findings resulted from study design rather than lack of actual morphine benefit. First, morphine could not reach the infarcted myocardium due to impaired coronary flow. However, we injected morphine into the coronary artery immediately after restoration of blood flow. In some patients morphine was administered locally at the site of the infarct lesion via thrombus aspiration catheter instead of via guiding catheter only, but subgroup analysis showed no significant difference in treatment effect of IC morphine according to method of administration. Local concentrations of morphine might be much higher with IC administration than with intravenous administration regardless of the use of thrombus aspiration catheter. Second, whether the dose of morphine was adequate is uncertain. Due to lack of data, we arbitrarily chose 3&#x000a0;mg of morphine sulfate, which was a little bit smaller than the conventional intravenous dose. Third, some patients received intravenous morphine at the emergency room for pain control. We did not exclude those receiving morphine before randomization because pain control is 1 of the important treatment goals in patients with STEMI, and the use of morphine is frequently inevitable in real&#x02010;world practice. Subgroup analysis showed a significant interaction between the treatment effect of IC morphine during primary PCI and prior use of morphine. Prior use of morphine per se might have protective effects on myocardial infarct size, or the accumulated dose might reach therapeutic concentration. However, these findings should be interpreted with caution and are hypothesis generating at best. We cannot exclude a possibility of play of chance.</p><p>The potential beneficial effects of morphine might be negated by a pleomorphic effect that counterbalances its cardioprotective effect. Several pharmacokinetic and pharmacodynamic studies have proposed adverse effects of morphine in association with delayed activity of P2Y<sub>12</sub> receptor inhibitors by its delaying absorption in the gastrointestinal tract.<xref rid="jah32155-bib-0026" ref-type="ref">26</xref>, <xref rid="jah32155-bib-0027" ref-type="ref">27</xref> A recent study reported adverse effects of morphine in terms of larger infarct size, higher extent of MVO, and lower myocardial salvage index.<xref rid="jah32155-bib-0028" ref-type="ref">28</xref> However, morphine did not show any harmful effects in our study. Taken together, it seems to be unlikely that morphine administration during primary PCI is protective in patients undergoing primary PCI under current standard practices. Our primary end point of infarct size measured by CMR is a widely accepted gold standard for myocardial damage and is significantly correlated with long&#x02010;term clinical outcomes in patients with STEMI.<xref rid="jah32155-bib-0029" ref-type="ref">29</xref> However, because morphine delays absorption of P2Y<sub>12</sub> receptor inhibitors, a large study is needed to investigate the consequence of reduced inhibition of platelet activation by morphine administration.</p><sec id="jah32155-sec-0017"><title>Study Limitations</title><p>There are some limitations of the current study. First, all study drugs were open label, but primary outcome measurement was blinded. Second, there is a chance of selection bias because CMR analysis was not available for all randomized patients. However, this study is comparable to other studies in the acquisition rate of CMR (87.9%).<xref rid="jah32155-bib-0030" ref-type="ref">30</xref>, <xref rid="jah32155-bib-0031" ref-type="ref">31</xref> Third, the primary outcome of our study was measured at a relatively early phase after STEMI, and only 6&#x02010;month clinical outcomes were evaluated. Assessment of long&#x02010;term results regarding ventricular remodeling after infarct maturation and long&#x02010;term clinical events is still needed.</p></sec></sec><sec id="jah32155-sec-0018"><title>Conclusions</title><p>In this prospective randomized trial, IC morphine could not reduce myocardial infarct size compared with the control in STEMI patients undergoing primary PCI. However, it may be worthwhile to investigate whether different dose, timing, or route of administration of morphine would reduce myocardial infarct size.</p></sec><sec id="jah32155-sec-0019"><title>Sources of Funding</title><p>This study was supported by the Sungkyunkwan University Foundation for Corporate Collaboration (CB28051).</p></sec><sec id="jah32155-sec-0020"><title>Disclosures</title><p>None.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="jah32155-sup-0001"><caption><p>
<bold>Table&#x000a0;S1.</bold> In&#x02010;Hospital Complications</p><p>
<bold>Table&#x000a0;S2.</bold> Pharmacology Therapy</p></caption><media xlink:href="JAH3-6-e005426-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="jah32155-bibl-0001"><title>References</title><ref id="jah32155-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah32155-cit-0001">
<string-name>
<surname>Pedersen</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Butrymovich</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Kelbaek</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wachtell</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Helqvist</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kastrup</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Holmvang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Clemmensen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Engstrom</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Grande</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Saunamaki</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Jorgensen</surname>
<given-names>E</given-names>
</string-name>. <article-title>Short&#x02010; and long&#x02010;term cause of death in patients treated with primary PCI for STEMI</article-title>. <source>J Am Coll Cardiol</source>. <year>2014</year>;<volume>64</volume>:<fpage>2101</fpage>&#x02013;<lpage>2108</lpage>.<pub-id pub-id-type="pmid">25457398</pub-id></mixed-citation></ref><ref id="jah32155-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah32155-cit-0002">
<string-name>
<surname>Weir</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>McMurray</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Velazquez</surname>
<given-names>EJ</given-names>
</string-name>. <article-title>Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance</article-title>. <source>Am J Cardiol</source>. <year>2006</year>;<volume>97</volume>:<fpage>13F</fpage>&#x02013;<lpage>25F</lpage>.<pub-id pub-id-type="pmid">16377275</pub-id></mixed-citation></ref><ref id="jah32155-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah32155-cit-0003">
<string-name>
<surname>Poli</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fetiveau</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Vandoni</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>del Rosso</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>D'Urbano</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Seveso</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Cafiero</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>De Servi</surname>
<given-names>S</given-names>
</string-name>. <article-title>Integrated analysis of myocardial blush and ST&#x02010;segment elevation recovery after successful primary angioplasty: real&#x02010;time grading of microvascular reperfusion and prediction of early and late recovery of left ventricular function</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>106</volume>:<fpage>313</fpage>&#x02013;<lpage>318</lpage>.<pub-id pub-id-type="pmid">12119246</pub-id></mixed-citation></ref><ref id="jah32155-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah32155-cit-0004">
<string-name>
<surname>Stone</surname>
<given-names>GW</given-names>
</string-name>, <string-name>
<surname>Peterson</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Lansky</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Dangas</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Mehran</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Leon</surname>
<given-names>MB</given-names>
</string-name>. <article-title>Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction</article-title>. <source>J Am Coll Cardiol</source>. <year>2002</year>;<volume>39</volume>:<fpage>591</fpage>&#x02013;<lpage>597</lpage>.<pub-id pub-id-type="pmid">11849856</pub-id></mixed-citation></ref><ref id="jah32155-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah32155-cit-0005">
<string-name>
<surname>Garcia&#x02010;Dorado</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Piper</surname>
<given-names>HM</given-names>
</string-name>. <article-title>Postconditioning: reperfusion of &#x0201c;reperfusion injury&#x0201d; after hibernation</article-title>. <source>Cardiovasc Res</source>. <year>2006</year>;<volume>69</volume>:<fpage>1</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">16337162</pub-id></mixed-citation></ref><ref id="jah32155-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah32155-cit-0006">
<string-name>
<surname>Piper</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Garcia&#x02010;Dorado</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ovize</surname>
<given-names>M</given-names>
</string-name>. <article-title>A fresh look at reperfusion injury</article-title>. <source>Cardiovasc Res</source>. <year>1998</year>;<volume>38</volume>:<fpage>291</fpage>&#x02013;<lpage>300</lpage>.<pub-id pub-id-type="pmid">9709390</pub-id></mixed-citation></ref><ref id="jah32155-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah32155-cit-0007">
<string-name>
<surname>Garcia&#x02010;Dorado</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Rodriguez&#x02010;Sinovas</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ruiz&#x02010;Meana</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Inserte</surname>
<given-names>J</given-names>
</string-name>. <article-title>Protection against myocardial ischemia&#x02010;reperfusion injury in clinical practice</article-title>. <source>Rev Esp Cardiol (Engl Ed)</source>. <year>2014</year>;<volume>67</volume>:<fpage>394</fpage>&#x02013;<lpage>404</lpage>.<pub-id pub-id-type="pmid">24774733</pub-id></mixed-citation></ref><ref id="jah32155-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah32155-cit-0008">
<string-name>
<surname>Gross</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Hsu</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Gross</surname>
<given-names>GJ</given-names>
</string-name>. <article-title>Opioid&#x02010;induced cardioprotection occurs via glycogen synthase kinase &#x003b2; inhibition during reperfusion in intact rat hearts</article-title>. <source>Circ Res</source>. <year>2004</year>;<volume>94</volume>:<fpage>960</fpage>&#x02013;<lpage>966</lpage>.<pub-id pub-id-type="pmid">14976126</pub-id></mixed-citation></ref><ref id="jah32155-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah32155-cit-0009">
<string-name>
<surname>Obame</surname>
<given-names>FN</given-names>
</string-name>, <string-name>
<surname>Plin&#x02010;Mercier</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Assaly</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zini</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Dubois&#x02010;Rande</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Berdeaux</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Morin</surname>
<given-names>D</given-names>
</string-name>. <article-title>Cardioprotective effect of morphine and a blocker of glycogen synthase kinase 3&#x003b2;, SB216763 [3&#x02010;(2,4&#x02010;dichlorophenyl)&#x02010;4(1&#x02010;methyl&#x02010;1H&#x02010;indol&#x02010;3&#x02010;yl)&#x02010;1H&#x02010;pyrrole&#x02010;2,5&#x02010;dione], via inhibition of the mitochondrial permeability transition pore</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2008</year>;<volume>326</volume>:<fpage>252</fpage>&#x02013;<lpage>258</lpage>.<pub-id pub-id-type="pmid">18434587</pub-id></mixed-citation></ref><ref id="jah32155-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah32155-cit-0010">
<string-name>
<surname>Forster</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kuno</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Solenkova</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Felix</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Krieg</surname>
<given-names>T</given-names>
</string-name>. <article-title>The &#x003b4;&#x02010;opioid receptor agonist DADLE at reperfusion protects the heart through activation of pro&#x02010;survival kinases via EGF receptor transactivation</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. <year>2007</year>;<volume>293</volume>:<fpage>H1604</fpage>&#x02013;<lpage>H1608</lpage>.<pub-id pub-id-type="pmid">17545478</pub-id></mixed-citation></ref><ref id="jah32155-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah32155-cit-0011">
<string-name>
<surname>Wohrle</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Grebe</surname>
<given-names>OC</given-names>
</string-name>, <string-name>
<surname>Nusser</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Al&#x02010;Khayer</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Schaible</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kochs</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hombach</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Hoher</surname>
<given-names>M</given-names>
</string-name>. <article-title>Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>107</volume>:<fpage>1840</fpage>&#x02013;<lpage>1843</lpage>.<pub-id pub-id-type="pmid">12682003</pub-id></mixed-citation></ref><ref id="jah32155-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah32155-cit-0012">
<string-name>
<surname>Lee</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Low</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tai</surname>
<given-names>BC</given-names>
</string-name>, <string-name>
<surname>Co</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>MY</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>YT</given-names>
</string-name>, <string-name>
<surname>Tan</surname>
<given-names>HC</given-names>
</string-name>. <article-title>Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non&#x02010;urgent percutaneous coronary intervention: a prospective randomized study</article-title>. <source>Eur Heart J</source>. <year>2007</year>;<volume>28</volume>:<fpage>19</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">17132650</pub-id></mixed-citation></ref><ref id="jah32155-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah32155-cit-0013">
<string-name>
<surname>Thiele</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Schindler</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Friedenberger</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Eitel</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Furnau</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Grebe</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Erbs</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Linke</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mobius&#x02010;Winkler</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kivelitz</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Schuler</surname>
<given-names>G</given-names>
</string-name>. <article-title>Intracoronary compared with intravenous bolus abciximab application in patients with ST&#x02010;elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST&#x02010;elevation myocardial infarction trial</article-title>. <source>Circulation</source>. <year>2008</year>;<volume>118</volume>:<fpage>49</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">18559698</pub-id></mixed-citation></ref><ref id="jah32155-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah32155-cit-0014">
<string-name>
<surname>Hahn</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>YB</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>EK</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Bae</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>WY</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Bae</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>An</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Oh</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Hwang</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Ryu</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Gwon</surname>
<given-names>HC</given-names>
</string-name>. <article-title>Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning on myocardial reperfusion in patients with ST&#x02010;segment elevation myocardial infarction (POST) randomized trial</article-title>. <source>Circulation</source>. <year>2013</year>;<volume>128</volume>:<fpage>1889</fpage>&#x02013;<lpage>1896</lpage>.<pub-id pub-id-type="pmid">24068776</pub-id></mixed-citation></ref><ref id="jah32155-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah32155-cit-0015">
<string-name>
<surname>Kim</surname>
<given-names>EK</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>YB</given-names>
</string-name>, <string-name>
<surname>Hahn</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Choe</surname>
<given-names>YH</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Gwon</surname>
<given-names>HC</given-names>
</string-name>. <article-title>A protective role of early collateral blood flow in patients with ST&#x02010;segment elevation myocardial infarction</article-title>. <source>Am Heart J</source>. <year>2016</year>;<volume>171</volume>:<fpage>56</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">26699601</pub-id></mixed-citation></ref><ref id="jah32155-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah32155-cit-0016">
<string-name>
<surname>O'Gara</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Kushner</surname>
<given-names>FG</given-names>
</string-name>, <string-name>
<surname>Ascheim</surname>
<given-names>DD</given-names>
</string-name>, <string-name>
<surname>Casey</surname>
<given-names>DE</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>de Lemos</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Ettinger</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Fang</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Fesmire</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Franklin</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Granger</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Krumholz</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Linderbaum</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Morrow</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Newby</surname>
<given-names>LK</given-names>
</string-name>, <string-name>
<surname>Ornato</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Ou</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Radford</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Tamis&#x02010;Holland</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Tommaso</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Tracy</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Woo</surname>
<given-names>YJ</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>DX</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Jacobs</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Halperin</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Albert</surname>
<given-names>NM</given-names>
</string-name>, <string-name>
<surname>Brindis</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Creager</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>DeMets</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Guyton</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Hochman</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Kovacs</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Kushner</surname>
<given-names>FG</given-names>
</string-name>, <string-name>
<surname>Ohman</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Stevenson</surname>
<given-names>WG</given-names>
</string-name>, <string-name>
<surname>Yancy</surname>
<given-names>CW</given-names>
</string-name>; <collab collab-type="authors">American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</collab>
. <article-title>2013 ACCF/AHA guideline for the management of ST&#x02010;elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title>. <source>Circulation</source>. <year>2013</year>;<volume>127</volume>:<fpage>e362</fpage>&#x02013;<lpage>e425</lpage>.<pub-id pub-id-type="pmid">23247304</pub-id></mixed-citation></ref><ref id="jah32155-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah32155-cit-0017">
<string-name>
<surname>Song</surname>
<given-names>YB</given-names>
</string-name>, <string-name>
<surname>Hahn</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Gwon</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>SY</given-names>
</string-name>, <string-name>
<surname>Choe</surname>
<given-names>YH</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>SH</given-names>
</string-name>. <article-title>Upstream high&#x02010;dose tirofiban does not reduce myocardial infarct size in patients undergoing primary percutaneous coronary intervention: a magnetic resonance imaging pilot study</article-title>. <source>Clin Cardiol</source>. <year>2009</year>;<volume>32</volume>:<fpage>321</fpage>&#x02013;<lpage>326</lpage>.<pub-id pub-id-type="pmid">19569068</pub-id></mixed-citation></ref><ref id="jah32155-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah32155-cit-0018">
<string-name>
<surname>Ortiz&#x02010;Perez</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Meyers</surname>
<given-names>SN</given-names>
</string-name>, <string-name>
<surname>Davidson</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Bonow</surname>
<given-names>RO</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>E</given-names>
</string-name>. <article-title>Determinants of myocardial salvage during acute myocardial infarction: evaluation with a combined angiographic and CMR myocardial salvage index</article-title>. <source>JACC Cardiovasc Imaging</source>. <year>2010</year>;<volume>3</volume>:<fpage>491</fpage>&#x02013;<lpage>500</lpage>.<pub-id pub-id-type="pmid">20466344</pub-id></mixed-citation></ref><ref id="jah32155-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah32155-cit-0019">
<string-name>
<surname>Yellon</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Hausenloy</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Myocardial reperfusion injury</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>357</volume>:<fpage>1121</fpage>&#x02013;<lpage>1135</lpage>.<pub-id pub-id-type="pmid">17855673</pub-id></mixed-citation></ref><ref id="jah32155-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah32155-cit-0020">
<string-name>
<surname>Kim</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Woo</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Ha</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>WY</given-names>
</string-name>, <string-name>
<surname>Hwang</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>SU</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Im</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>W</given-names>
</string-name>. <article-title>Effect of myocardial protection of intracoronary adenosine and nicorandil injection in patients undergoing non&#x02010;urgent percutaneous coronary intervention: a randomized controlled trial</article-title>. <source>Int J Cardiol</source>. <year>2012</year>;<volume>158</volume>:<fpage>88</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">21256606</pub-id></mixed-citation></ref><ref id="jah32155-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah32155-cit-0021">
<string-name>
<surname>Selker</surname>
<given-names>HP</given-names>
</string-name>, <string-name>
<surname>Beshansky</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Sheehan</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Massaro</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Griffith</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>D'Agostino</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Ruthazer</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Atkins</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Sayah</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Levy</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Richards</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Aufderheide</surname>
<given-names>TP</given-names>
</string-name>, <string-name>
<surname>Braude</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Pirrallo</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Doyle</surname>
<given-names>DD</given-names>
</string-name>, <string-name>
<surname>Frascone</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Kosiak</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Leaming</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Van Gelder</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Walter</surname>
<given-names>GP</given-names>
</string-name>, <string-name>
<surname>Wayne</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Woolard</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Opie</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Rackley</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Apstein</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Udelson</surname>
<given-names>JE</given-names>
</string-name>. <article-title>Out&#x02010;of&#x02010;hospital administration of intravenous glucose&#x02010;insulin&#x02010;potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial</article-title>. <source>JAMA</source>. <year>2012</year>;<volume>307</volume>:<fpage>1925</fpage>&#x02013;<lpage>1933</lpage>.<pub-id pub-id-type="pmid">22452807</pub-id></mixed-citation></ref><ref id="jah32155-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah32155-cit-0022">
<string-name>
<surname>Yang</surname>
<given-names>XM</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Cui</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tandon</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kambayashi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Downey</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>MV</given-names>
</string-name>. <article-title>Platelet P2Y(1)(2) blockers confer direct postconditioning&#x02010;like protection in reperfused rabbit hearts</article-title>. <source>J Cardiovasc Pharmacol Ther</source>. <year>2013</year>;<volume>18</volume>:<fpage>251</fpage>&#x02013;<lpage>262</lpage>.<pub-id pub-id-type="pmid">23233653</pub-id></mixed-citation></ref><ref id="jah32155-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah32155-cit-0023">
<collab collab-type="authors">Task Force on the management of ST segment elevation acute myocardial infarction of the European Society of Cardiology</collab>
, <string-name>
<surname>Steg</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>James</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Atar</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Badano</surname>
<given-names>LP</given-names>
</string-name>, <string-name>
<surname>Blomstrom&#x02010;Lundqvist</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Borger</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Di Mario</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dickstein</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ducrocq</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Fernandez&#x02010;Aviles</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gershlick</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Giannuzzi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Halvorsen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Huber</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Juni</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kastrati</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Knuuti</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lenzen</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Mahaffey</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Valgimigli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>van &#x02018;t Hof</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Widimsky</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Zahger</surname>
<given-names>D</given-names>
</string-name>. <article-title>ESC guidelines for the management of acute myocardial infarction in patients presenting with ST&#x02010;segment elevation</article-title>. <source>Eur Heart J</source>. <year>2012</year>;<volume>33</volume>:<fpage>2569</fpage>&#x02013;<lpage>2619</lpage>.<pub-id pub-id-type="pmid">22922416</pub-id></mixed-citation></ref><ref id="jah32155-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah32155-cit-0024">
<string-name>
<surname>Rouby</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Eurin</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Glaser</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Guillosson</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Nafziger</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Guesde</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Viars</surname>
<given-names>P</given-names>
</string-name>. <article-title>Hemodynamic and metabolic effects of morphine in the critically ill</article-title>. <source>Circulation</source>. <year>1981</year>;<volume>64</volume>:<fpage>53</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="pmid">7237725</pub-id></mixed-citation></ref><ref id="jah32155-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jah32155-cit-0025">
<string-name>
<surname>Rentoukas</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Giannopoulos</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kaoukis</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kossyvakis</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Raisakis</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Driva</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Panagopoulou</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Tsarouchas</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Vavetsi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pyrgakis</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Deftereos</surname>
<given-names>S</given-names>
</string-name>. <article-title>Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2010</year>;<volume>3</volume>:<fpage>49</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">20129568</pub-id></mixed-citation></ref><ref id="jah32155-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jah32155-cit-0026">
<string-name>
<surname>Kubica</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Adamski</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ostrowska</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sikora</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kubica</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Sroka</surname>
<given-names>WD</given-names>
</string-name>, <string-name>
<surname>Stankowska</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Buszko</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Navarese</surname>
<given-names>EP</given-names>
</string-name>, <string-name>
<surname>Jilma</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Siller&#x02010;Matula</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Marszall</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Rosc</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kozinski</surname>
<given-names>M</given-names>
</string-name>. <article-title>Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double&#x02010;blind, placebo&#x02010;controlled IMPRESSION trial</article-title>. <source>Eur Heart J</source>. <year>2016</year>;<volume>37</volume>:<fpage>245</fpage>&#x02013;<lpage>252</lpage>.<pub-id pub-id-type="pmid">26491112</pub-id></mixed-citation></ref><ref id="jah32155-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jah32155-cit-0027">
<string-name>
<surname>Parodi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bellandi</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Xanthopoulou</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Capranzano</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Capodanno</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Valenti</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Stavrou</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Migliorini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Antoniucci</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Tamburino</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Alexopoulos</surname>
<given-names>D</given-names>
</string-name>. <article-title>Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST&#x02010;elevation acute myocardial infarction undergoing primary percutaneous coronary intervention</article-title>. <source>Circ Cardiovasc Interv</source>. <year>2015</year>;<volume>8</volume>:<fpage>e001593</fpage>.<pub-id pub-id-type="pmid">25552565</pub-id></mixed-citation></ref><ref id="jah32155-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jah32155-cit-0028">
<string-name>
<surname>de Waha</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Eitel</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Desch</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fuernau</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lurz</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Urban</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Schuler</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Thiele</surname>
<given-names>H</given-names>
</string-name>. <article-title>Intravenous morphine administration and reperfusion success in ST&#x02010;elevation myocardial infarction: insights from cardiac magnetic resonance imaging</article-title>. <source>Clin Res Cardiol</source>. <year>2015</year>;<volume>104</volume>:<fpage>727</fpage>&#x02013;<lpage>734</lpage>.<pub-id pub-id-type="pmid">25725777</pub-id></mixed-citation></ref><ref id="jah32155-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jah32155-cit-0029">
<string-name>
<surname>Stone</surname>
<given-names>GW</given-names>
</string-name>, <string-name>
<surname>Selker</surname>
<given-names>HP</given-names>
</string-name>, <string-name>
<surname>Thiele</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Udelson</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Ohman</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Maehara</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Eitel</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Granger</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Jenkins</surname>
<given-names>PL</given-names>
</string-name>, <string-name>
<surname>Nichols</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ben&#x02010;Yehuda</surname>
<given-names>O</given-names>
</string-name>. <article-title>Relationship between infarct size and outcomes following primary PCI: patient&#x02010;level analysis from 10 randomized trials</article-title>. <source>J Am Coll Cardiol</source>. <year>2016</year>;<volume>67</volume>:<fpage>1674</fpage>&#x02013;<lpage>1683</lpage>.<pub-id pub-id-type="pmid">27056772</pub-id></mixed-citation></ref><ref id="jah32155-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jah32155-cit-0030">
<string-name>
<surname>Stone</surname>
<given-names>GW</given-names>
</string-name>, <string-name>
<surname>Maehara</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Witzenbichler</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Godlewski</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Parise</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Dambrink</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Ochala</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Carlton</surname>
<given-names>TW</given-names>
</string-name>, <string-name>
<surname>Cristea</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Wolff</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Brener</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Chowdhary</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>El&#x02010;Omar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Neunteufl</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Metzger</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Karwoski</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Dizon</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Mehran</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Gibson</surname>
<given-names>CM</given-names>
</string-name>; <collab collab-type="authors">INFUSE&#x02010;AMI Investigators</collab>
. <article-title>Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE&#x02010;AMI randomized trial</article-title>. <source>JAMA</source>. <year>2012</year>;<volume>307</volume>:<fpage>1817</fpage>&#x02013;<lpage>1826</lpage>.<pub-id pub-id-type="pmid">22447888</pub-id></mixed-citation></ref><ref id="jah32155-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jah32155-cit-0031">
<string-name>
<surname>Patel</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Smalling</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Thiele</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Barnhart</surname>
<given-names>HX</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Chandra</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Chew</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>French</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Perera</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ohman</surname>
<given-names>EM</given-names>
</string-name>. <article-title>Intra&#x02010;aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial</article-title>. <source>JAMA</source>. <year>2011</year>;<volume>306</volume>:<fpage>1329</fpage>&#x02013;<lpage>1337</lpage>.<pub-id pub-id-type="pmid">21878431</pub-id></mixed-citation></ref></ref-list></back></article>